Paeds Vivas · allergy-and-immunology
Complement deficiencies — branching viva
Branching viva on complement deficiencies in children: recognising the three clinical fingerprints that earn a complement work-up, screening with CH50 and AP50, localising the block to a pathway, and tailoring prevention to the site of the defect — meningococcal vaccination and antibiotic prophylaxis for terminal-pathway loss, and C1-inhibitor-directed therapy for hereditary angioedema.
On this page & tools
Target exams
Opening question
Take me through your framework when a child presents with recurrent invasive meningococcal disease and you suspect a complement deficiency. What are the three clinical fingerprints that earn a complement work-up? [1] [9]
Branch 1 — the likely diagnosis
The boy is otherwise completely well, with normal growth and no other infections, but has had two episodes of invasive meningococcal disease and a family history of male meningitis deaths. His CH50 is undetectable with a normal AP50. What is the most likely category of diagnosis, why is he "otherwise well", and which pathway is affected? [9] [10]
Branch 2 — confirming the defect
How will you confirm this diagnosis, and why does a normal C3 and C4 not exclude it? What does the absent CH50 with a normal AP50 tell you that the C3/C4 alone does not? Which second-line tests identify the missing component, and how does genetic testing inform family screening? [1] [5]
Branch 3 — long-term management and family screening
Outline the principles of long-term management: meningococcal vaccination, antibiotic prophylaxis, the emergency antibiotic supply, and the prognosis. Why is the protection imperfect despite vaccination? Which family members need screening, and why does the X-linked pattern of properdin deficiency change the screening question? [9] [10]
Branch 4 — the contrasting case (the trap)
Now picture a twelve-year-old with angioedema of the tongue, no urticaria, a family history of facial swelling, and no response to adrenaline, antihistamines or corticosteroids. What is the diagnosis, why did the anaphylaxis regimen fail, and what is the correct acute therapy? How does the management of hereditary angioedema differ from the infection-defence complement deficiencies? [7] [8]
Closing — the general rule
In one sentence, what is the single rule that decides the screening test for a suspected complement deficiency, and what is the single rule that decides the acute therapy for angioedema without urticaria? Why do the two commonest errors — sending a lone C3/C4, and treating hereditary angioedema with anaphylaxis drugs — persist? [1] [8]
References
- [1]Walport MJ. Complement. First of two parts. N Engl J Med, 2001.PMID 11287977
- [2]Walport MJ. Complement. Second of two parts. N Engl J Med, 2001.PMID 11297706
- [3]Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol, 2009.PMID 19481265
- [5]Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol, 2022.PMID 36198931
- [7]Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med, 2008.PMID 18768946
- [8]Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. World Allergy Organ J, 2022.PMID 35497649
- [9]Rauscher CK, Fajt ML, Bryk JA, et al. Clinical implications of C6 complement component deficiency. Allergy Asthma Proc, 2020.PMID 32867893
- [10]Ladhani SN, Campbell H, Lucidarme J, et al. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). BMC Infect Dis, 2019.PMID 31200658